State Street
APGE icon

State Street’s Apogee Therapeutics APGE Stock Holding History

State Street’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305M Buy
2,297,743
+134,779
+6% +$12.1M 0.01% 805
2026
Q1 		$182M Buy
2,162,964
+472,778
+28% +$34.3M 0.01% 992
2025
Q4 		$128M Buy
1,690,186
+34,638
+2% +$2.18M ﹤0.01% 1217
2025
Q3 		$65.8M Buy
1,655,548
+396,290
+31% +$15.1M ﹤0.01% 1593
2025
Q2 		$54.7M Sell
1,259,258
-54,492
-4% -$2.07M ﹤0.01% 1632
2025
Q1 		$49.1M Sell
1,313,750
-153,364
-10% -$5.93M ﹤0.01% 1645
2024
Q4 		$66.5M Buy
1,467,114
+55,475
+4% +$2.83M ﹤0.01% 1577
2024
Q3 		$82.9M Sell
1,411,639
-149,723
-10% -$7.17M ﹤0.01% 1435
2024
Q2 		$61.4M Buy
1,561,362
+213,565
+16% +$10.4M ﹤0.01% 1554
2024
Q1 		$89.6M Buy
1,347,797
+968,527
+255% +$42.3M ﹤0.01% 1379
2023
Q4 		$10.6M Buy
379,270
+175,753
+86% +$3.52M ﹤0.01% 2557
2023
Q3 		$4.33M Buy
+203,517
New +$4.48M ﹤0.01% 2987

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

State Street's APGE Position: Q2 2026 in Review

State Street increased its Apogee Therapeutics (APGE) stake by 6.2% in Q2 2026, buying an estimated $12.1M and bringing the position to 2,297,743 shares worth $305M. The position accounts for 0.01% of the portfolio, ranked #805.

State Street first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • State Street held 2,297,743 shares of Apogee Therapeutics worth $305M as of Q2 2026.
  • State Street bought 134,779 Apogee Therapeutics shares in Q2 2026, an estimated $12.1M.
  • Apogee Therapeutics made up 0.01% of State Street's portfolio in Q2 2026, its #805 holding.
  • State Street first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.